Clinical trials: in India
Metastatic Non-small Cell Lung Cancer
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in…
- Trial name
- eVOLVE-Lung02 (NCT05984277)
- Testing
- Volrustomig, Pembrolizumab, Carboplatin
- Where
- 231 sites in United States, Argentina and 23 more
- Volunteers
- 895 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC )
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy .
- Conditions
- Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT07476287
- Testing
- PF-08634404, Chemotherapy
- Where
- 61 sites in United States, Australia and 10 more
- Volunteers
- 40 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with…
- Trial name
- AERIFY-2 (NCT04751487)
- Testing
- Itepekimab SAR440340
- Where
- 238 sites in United States, Argentina and 27 more
- Volunteers
- 1,234 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Trial name
- NCT07100080
- Testing
- Iza-bren, Carboplatin, Cisplatin
- Where
- 187 sites in United States, Argentina and 23 more
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
Headache Disorders
Smartphone Use Restriction as Treatment of Primary Headache
The goal of this clinical trial is to study smartphone use restriction as a treatment modality in patients of primary headache. The main question[s] it aims to answer are: 1.
- Trial name
- NCT06041997
- Testing
- Smartphone restriction
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences
Interstitial Lung Disease
Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD
Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area.
- Trial name
- GAZEBO-ILD (NCT07859839)
- Testing
- Gabapentin, Benzonatate 200 mg, Standard of care treatment for ILD
- Where
- India
- Volunteers
- 177 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Colorectal Cancer
A Single Center Evaluation of AI Enabled SureForm Robotic Stapler (SureformTM) Compared to Conventional Stapler for Colorectal Cancer Procedures
Robotic-assisted surgeries are especially valuable for colorectal pathologies because they offer better vision and control for surgical manipulation given the narrow operative region within the pelvis .Some of the iatrogenic risk…
- Trial name
- NCT07371832
- Testing
- AI-enabled SureForm™ Robotic Stapler, Conventional Laparoscopic Stapler
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Asian Institute of Gastroenterology, India
Hepatocellular Carcinoma
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
- Trial name
- EMERALD-2 (NCT03847428)
- Testing
- Durvalumab, Bevacizumab
- Where
- 217 sites in United States, Australia and 22 more
- Volunteers
- 908 people
- Sponsor
- AstraZeneca
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer…
- Conditions
- Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- Trial name
- NCT07222566
- Testing
- PF-08634404, Pembrolizumab, Chemotherapy Regimen 1
- Where
- 484 sites in United States, Argentina and 18 more
- Volunteers
- 1,410 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
This study aims to evaluate the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C…
- Trial name
- KontRASt-06 (NCT05445843)
- Testing
- JDQ443
- Where
- 45 sites in United States, Argentina and 17 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Hirayama Disease
Cervical Fixation Surgery Cervical Collar for Management of Hirayama Disease: A Randomized Study
The goal of this clinical trial] is to compare cervical collar versus neck stabilization surgery in diagnosed patients of Hirayama disease who have been reporting worsening of problems in the past six months.
- Trial name
- NCT05959980
- Testing
- Posterior cervical fixation surgery
- Where
- India
- Volunteers
- 80 people
- Sponsor
- All India Institute of Medical Sciences
Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India
This study will evaluate the safety of selpercatinib in participants with RET-altered cancers in India. The study will also assess the number of changes and why participants stop study treatment.
- Trial name
- NCT07822880
- Testing
- Selpercatinib
- Where
- 10 sites in India
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- NCT06292013
- Testing
- Lepodisiran Sodium
- Where
- 928 sites in United States, Argentina and 26 more
- Volunteers
- 17,300 people
- Sponsor
- Eli Lilly and Company
Plaque-Induced Gingivitis, Orthodontic Treatment
Clinical Outcomes of Different Mouth Rinses During Clear Aligner Orthodontic Therapy
This pilot randomized controlled clinical trial will evaluate the feasibility and preliminary clinical effects of three mouth rinses-alum, Triphala-based herbal mouth rinse, and 0.2% chlorhexidine-in adults undergoing clear…
- Trial name
- NCT07865416
- Testing
- Alum Mouth Rinse, Triphala-based Herbal Mouth Rinse, Chlorhexidine mouth rinse
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Manav Rachna International Institute of Research and Studies
Overweight, Prediabetic State
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and…
- Conditions
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
- Trial name
- ATTAIN-NOW (NCT07794579)
- Testing
- Orforglipron
- Where
- 180 sites in United States, Argentina and 10 more
- Volunteers
- 2,001 people
- Sponsor
- Eli Lilly and Company
Reversible Pulpitis
Direct Pulp Capping Agent on Human Pulp Tissue
This in- vivo study was conducted to evaluate the response of human pulp tissue following direct pulp capping using four different pulp capping agents in premolars scheduled for extraction in patients undergoing orthodontic…
- Trial name
- NCT06435065
- Testing
- Biodentine, Mineral Tri-Oxide Aggregate, THERACAL LC
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- DR SURINDER SACHDEVA
Diabetes Mellitus, Type 2, Diabetes Melletus
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders
- Trial name
- ACHIEVE-RAM (NCT07613307)
- Testing
- Orforglipron
- Where
- 40 sites in India, Saudi Arabia and 2 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Pulmonary Disease, Chronic Obstructive
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when…
- Trial name
- RENEW-COPD (NCT07759245)
- Testing
- Brenipatide, Standard of Care
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.